ISRCTN31208535已完成2 期
A randomised controlled trial of calcium channel blockade with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia.
Belfast Health and Social Care Trust (UK)0 个研究点目标入组 588 人开始时间: 2014年4月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 588
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 09/11/2015:
- •1. Dementia syndrome according to the criteria a, b & d from code 290.4 of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
- •2. Evidence of one or more clinical features in support of SIVD such as executive dysfunction, mood or gait disturbance or focal neurological signs
- •3. Multiple lacunae (>2) or diffuse lesions reaching a mean score of 2-3 across brain regions identified on baseline MRI scan.
- •4. sMMSE score between 15 and 26 (inclusive).
- •5. Age = 50
- •6. If patients taking a cholinesterase inhibitor or memantine, dose stable for at least three months.
- •7. If patients taking antidepressants, dose stable for at least four weeks.
- •8. CT or MRI scan consistent with the probable diagnosis of SIVD providing there has been no significant clinical change since the scan.
- •9. Patient has resident family or professional carer or is visited at least twice a week by carer.
- •10. Fluency in English is essential as the study requires questionnaires to be completed.
- •11. Likely to be able to participate in all scheduled evaluations and complete all required tests.
- •12. Provision of appropriate consent.
- •13. Presence of an informant, aged 18 years or over who is willing to participate in the study.
- •Previous inclusion criteria:
- •1. Dementia syndrome according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
- •2. Evidence of one or more clinical features in support of SIVD such as executive dysfunction, mood or gait disturbance or focal neurological signs
- •3. Multiple lacunae (>2) or diffuse lesions reaching a mean score of 2-3 across brain regions identified on baseline MRI scan
- •4. sMMSE score between 20 and 26 (inclusive)
- •5. Age 50 years or older
- •6. If patients taking a cholinesterase inhibitor or memantine, dose stable for at least three months
- •7. If patients taking antidepressants, dose stable for at least four weeks
- •8. Diagnosis of probable SIVD with supportive imaging (CT or MRI) within last 24 months
- •9. Patient has resident family or professional carer or is visited at least twice a week by carer
- •10. Fluency in English and evidence of adequate premorbid intellectual functioning
- •11. Likely to be able to participate in all scheduled evaluations and complete all required tests
- •12. Provision of appropriate consent
- •13. Presence of an informant who is willing to participate in the study
排除标准
- •Current exclusion criteria as of 09/11/2015:
- •1. Severe, unstable or poorly controlled medical conditions apparent from physical examination or clinical history.
- •2. Moderate/severe heart disease or severe hepatic disease.
- •3. Significant renal insufficiency; estimated glomerular filtration rate (eGFR) <30ml/min.
- •4. Blood pressure (sitting) exceeds 160 mmHg systolic and/or 110 mmHg diastolic.
- •5. Systolic blood pressure (sitting) is less than 110mmHg.
- •6. Infarction involving the cortex on MRI scan.
- •7. Cerebrovascular event within the last six months.
- •8. Myocardial infarction within the last three months.
- •9. Already taking any calcium channel blocker.
- •10. Contraindications to a calcium channel blocker as per Summary of Product Characteristics (SPC)
- •11. Patient is unable to take trial medications.
- •12. Pregnant women or women who may possibly become pregnant (pre-menopausal). Females must be postmenopausal (no menses for = 12 months without an alternative medical cause) to participate in the study.
- •13. Female patients who are breastfeeding will be excluded.
- •14. AD is considered to be the primary diagnosis: i.e. a predominantly amnestic presentation or evidence of an amnestic (pre-dementia) phase or strong biomarker evidence to support a diagnosis of AD. Patients with severe hippocampal atrophy on MRI (Scheltens GR 3 and 4 on both sides (i.e. a total score (left plus right) of 6 or more) will be excluded.
- •15. Significant neurological disease that may affect cognition other than SIVD or AD as a concurrent pathology.
- •16. Current presence of a clinically significant major psychiatric disorder (e.g. Major Depressive Disorder) according to the criteria of the DSM-IV.
- •17. Current clinically significant systemic illness that is likely to result in deterioration of the patient’s condition or affect the patient’s safety during the study.
- •18. Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last three years.
- •19. Other clinically significant abnormality on physical, neurological, laboratory, examination that could compromise the study or be significantly detrimental to the patient (e.g. postural hypotension diagnosed within the last year which in the opinion of the PI would exclude the patient).
- •20. Alcohol or drug dependence or abuse within the last two years.
- •21. Treated with any other investigational medication or device within 60 days.
- •22. Patient taking simvastatin 40 mg or greater. A patient may be switched to an alternative statin and on stable dose for three months to meet inclusion criteria. A reduction in simvastatin dose solely for the purposes of eligibility is not permitted.
- •Previous exclusion criteria:
- •1. Severe, unstable or poorly controlled medical conditions apparent from physical examination or clinical history.
- •2. Moderate/severe heart disease or severe hepatic disease.
- •3. Significant renal insufficiency; estimated glomerular filtration rate (eGFR) <30ml/min.
- •4. Blood pressure exceeds 160 mmHg systolic and/or 110 mmHg diastolic.
- •5. Systolic blood pressure is less than 110mmHg.
- •6. Infarction involving the cortex on MRI scans.
- •7. Cerebrovascular event within the last six months.
- •8. Myocardial infarction within the last three months.
- •9. Already taking any calcium channel blocker.
- •10. Contraindications to a calcium channel blocker as per
研究者
相似试验
已完成
不适用
A Randomized, Controlled Study on Calcium Channel Blocker versus Angiotensin II Antagonists in the Hypertensive Patients with Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure with Angiotension II AntagonistsHypertension with type 2 diabetes mellitusJPRN-C000000017Central Coordinating Committee of ADVANCED-J Study Group300
已完成
不适用
High dose calcium channel blocker study for essential hypertensioEssential hypertensionJPRN-UMIN000011161Kazuomi Kario180
已完成
不适用
Study of calcium phosphate cement paste marker for breast conservation treatment in breast cancerbreast cancerJPRN-jRCTs032180042Ogino Ichiro100
已完成
4 期
Therapeutic effects of L/N type calcium channel blocker cilnidipine and L type calcium channel blockers on hypertensive patients with chronic kidney diseaseHypertension, Chronic kidney diseaseJPRN-UMIN000001593Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine60
已完成
不适用
A randomised double-blind controlled trial of BCNU as second-line therapy in metastatic oesophago-gastric, colorectal and pancreatic cancerColon, oesophagus, pancreas, rectum, stomach cancersCancerISRCTN58648476The Royal Marsden NHS Foundation Trust (UK)